STUDresearch · Peptide

Retatrutide

Also known as

LY3437943 · Reta · Triple agonist · Triple-G agonist · GLP-3 (informal community nickname) · GIP/GLP-1/glucagon triple agonist · Lilly triple agonist

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Lots of talk Systemic Subcutaneous Metabolic / GLP-1 class

Whole-body appetite, glucose and energy-expenditure effects; not a local tissue injection.

What people say “Reta” is an investigational triple GIP/GLP-1/glucagon agonist discussed by semaglutide/tirzepatide switchers and after tirzepatide plateaus.It is not an approved medicine; gray-vial reports are not trial-product evidence. Doses people talk about

Lower community discussion0.25–0.5 mg; 0.5–1 mg weekly

Micro-entry and already-lean maintenance cultures from the preserved notes; these are unvalidated reports, not proven recomp doses.

Higher community discussion2 mg entry; 4–9 mg holds; up to 12 mg weekly talk

Both strong response and nonresponse appear. Split schedules, source switching and prior incretins confound comparisons.

Phase 2 obesity arms1, 4, 8 or 12 mg SC once weekly

Protocol-defined trial arms, not community dosing. Phase 3 target sets and escalation details remain separately identified below.

No retatrutide amount is approved. Gray-vial identity and amount are unverified; separate accounts are not a safe progression or equivalent to trial drug.

Half-life & effect duration

Half-life in the body: Under-the-skin injectionAbout 6 days
Felt duration people report: Some appetite accountsStrongest curb over days 1–3, with more hunger near the end of the week
Other accountsMore even appetite control throughout the week

Timing context & sources

How it may feel Some reports describe strong appetite suppression, nausea or fatigue; others describe little change for weeks, including after 1–4 mg steps. Source switches complicate the stories.

Cycles people discuss Trials span many months of weekly use. Forums discuss long climbs, maintenance, breaks and sometimes short bodybuilding-style courses. Timing Weekly use dominates the discussion. People plan around nausea/fatigue days and eating or training routines; some describe late-week hunger and others no clear appetite response. Stacks Protein + resistance training: Default non-drug pairing to limit lean-mass loss during large deficits — more consensus than any peptide add-on. Access talk RUO label vs influencer dose talk: Vendors print “research use only / not for human consumption” while affiliate posts explain weekly pins. That split is the 2026 enforcement hook. Watch for GI (trial + community — most common): Nausea, vomiting, diarrhea, constipation, abdominal discomfort — dose-related, mostly mild–moderate, peak around escalation; lower starting dose (2 mg vs 4 mg) partially mitigated events in Phase 2.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 6 days in a small human study using subcutaneous retatrutide.

The trial used a defined study product; internet products cannot be assumed to match it.

Author-institution abstract reviewed, not the complete article. Small early trial funded by Eli Lilly; not a phase 2 dose source.

Urva et al.: phase 1b LY3437943 trial (opens in a new tab)Lancet 2022 abstract, Methods and Findings; DOI 10.1016/S0140-6736(22)02033-5Author-institution abstract reviewed, not the complete article. Small early trial funded by Eli Lilly; not a phase 2 dose source.

Felt duration people report

Some users describe several quieter-appetite days followed by stronger hunger near the end of the week.

The degree of late-week hunger differs between accounts; this is not a measured clearance time.

These are selected subjective reports, not an established typical duration or evidence for shortening intervals.

When Reta wears off I am ravenous — community accounts (opens in a new tab)Original post by Past-Tap2704 and reply by sanctified420 describing end-of-week appetiteUncontrolled reports and unverified products; the original post miscounts Tuesday-to-Tuesday as day eight. Neither that count nor surrounding stacking advice is adopted.

Other context in this card

Retatrutide: strong response versus nonresponse (opens in a new tab)Opening six-week 1 → 2 → 3 → 4 mg nonresponse, separate lower-amount responses and replies at 6/8/10 mg; TrainingMix4465 explicitly reports 1 mg weekly. Independent actual content inspection September 6; not all routes/frequencies stated.Selected unverified accounts, not prevalence; not every route/frequency is explicit. Replies also discuss higher amounts, so 0.5–4 mg is not the complete thread range.
Retatrutide: source change and abrupt symptoms (opens in a new tab)Opening report of little response before a source change and abrupt appetite/GI effects afterward. Independent actual post inspection September 6; unverified identity and prior exposure confound attribution.One uncontrolled account; cannot distinguish actual concentration, identity, accumulated exposure or a dose effect.
Retatrutide: Phase 2 obesity trial arms (opens in a new tab)Jastreboff 2023 original Phase 2 paper: Methods/Procedures, PDF pages 2–3; Safety, pages 5–7; Table 3, pages 10–11. Original full text inspected September 6, 2026.Defined human study product and protocol, not an approved or gray-vial schedule.
TRIUMPH-1: company-reported efficacy and safety (opens in a new tab)May 21, 2026 TRIUMPH-1 Efficacy Estimand Results and safety paragraph; exact 80-week efficacy and AE discontinuation data, selected 104-week extension. Independent actual original content inspection September 6.Sponsor topline, not an independently inspected peer-reviewed full Phase 3 paper; efficacy versus treatment-regimen estimands and selected extension differ.
TRIUMPH-1 congress: GI versus all-AE discontinuation (opens in a new tab)June 6, 2026 AEs Leading to Treatment Discontinuation: GI 2.2–4.6% versus 1.2% placebo. Independent actual congress content inspection September 6.Sponsor congress material; GI discontinuation and all-adverse-event discontinuation are different endpoints.

What people say 18

Appetite / food noise (community): Strong satiety and “less food thinking”; many switchers from sema/tirz describe equal or stronger quieting at comparable personal doses — anecdote, not head-to-head RCT. forum
Energy / “glucagon edge” lore: Community attributes extra heat / fat-mobilization feel to the glucagon arm vs dual agonists; mechanistic plausibility is discussed, subjective “hotter metabolism” reports are anecdotal. forum
Food-noise split: Some logs go quiet day 1 even at 0.5–1 mg; others still have chatter at 2 mg and argue tirz or cagri is the food-noise tool while reta is the scale tool. forum
Weight loss Phase 2 obesity (Jastreboff NEJM 2023, n=338, 48 weeks): LS mean change −8.7% (1 mg), −17.1% (combined 4 mg), −22.8% (combined 8 mg), −24.2% (12 mg) vs −2.1% placebo. trial
Same trial at 24 weeks (primary): −7.2% / −12.9% / −17.3% / −17.5% for 1 / 4 / 8 / 12 mg vs −1.6% placebo — already large mid-study. trial
Responder rates at 48 weeks (Phase 2): At 12 mg, ~100% ≥5%, ~93% ≥10%, ~83% ≥15% weight reduction; 8 mg also highly responder-dense. trial
Still dropping late (Phase 2): Higher-dose curves had not fully plateaued by later visits — drives “long titration / long runway” community talk. trial
Phase 3 TRIUMPH-1 (obesity/overweight, company topline): At 80 weeks the efficacy estimand gave 19.0/25.9/28.3% mean loss at 4/9/12 mg versus 2.2% placebo; treatment-regimen results were 17.6/23.7/25.0%. The 30.3% extension headline concerns selected high-BMI participants initially assigned 12 mg and continuing to 104 weeks at maximum tolerated 9/12 mg, not the whole original cohort. trial
TRIUMPH-4 (obesity + knee OA, earlier topline): High-dose arm reported ~28.7% mean weight loss at 68 weeks in public coverage — same molecule, different trial context. trial
T2D Phase 2 (Rosenstock Lancet 2023, ~36 weeks): Dose-dependent weight loss up to ~16.8–16.9% at 8–12 mg vs ~3% placebo and ~2% dulaglutide 1.5 mg; weight often continues after glycemic primary. trial
Glycemic Phase 2 T2D: HbA1c LS mean drops roughly −1.3% to −2.0% at 4–12 mg at 24 weeks (12 mg ~−2.02%) vs ~0% placebo and ~−1.41% dulaglutide 1.5 mg. trial
Liver fat / MASLD substudy (Sanyal et al., Nature Medicine 2024, n=98 from obesity Phase 2): Relative liver-fat change at 24 weeks −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) vs +0.3% placebo. trial
Liver fat at 48 weeks (same substudy): Relative reductions up to ~−86% at 12 mg; normal liver fat (<5%) achieved by ~86% (12 mg) at 24 weeks and ~93% at 48 weeks in reported figures. trial
Cardiometabolic (Phase 2 obesity): Improvements in waist, BP, lipids, and related markers tracking the weight loss; ambulatory BP monitored in protocol. trial
Body composition: Fat mass drives most of the scale change; lean mass still falls with large absolute loss — protein + resistance training is the default community countermeasure. Claims of uniquely superior muscle sparing vs tirzepatide are debated and not a settled Phase 3 fact. trial
Secondary program outcomes (Phase 3 talk): Knee OA pain (WOMAC) and obstructive sleep apnea (AHI) improvements reported alongside weight in TRIUMPH program communications. trial
Absolute loss framing (Lilly Phase 2 comms): Up to ~24.2% / ~57.8 lb mean at 12 mg / 48 weeks in the obesity program (baseline-dependent). trial
TRANSCEND-T2D-1 (Phase 3 T2D, topline): A1C reductions ~1.7–2.0% and weight loss up to ~16.8% at 40 weeks on 4 / 9 / 12 mg arms (efficacy estimand framing in Lilly comms). trial

Doses people talk about 20

Copied research ladders: Many logs mirror multi-mg weekly step-ups (e.g. low single-digit mg blocks climbing over months) — vendor charts differ hard. forum
Community microdose / gentle entry: 0.25 mg or 0.5 mg weekly for 1–4 weeks before joining the 1–2 mg band — especially after prior bad GLP-1/tirz experiences; not a trial arm. forum
Lean / recomp micro-maintenance (forum pattern): Some already-lean users report staying ~0.5–1 mg weekly for appetite edge without crushing protein intake — highly anecdotal, not trial-proven for recomp. forum
Split-dose debate: Some split the weekly total into two SC injections ~3–4 days apart (e.g., Mon/Thu) aiming for flatter peaks and less nausea; total weekly mg kept similar. Unvalidated vs once-weekly trial schedule. forum
Ceiling talk: Community “max” usually tracks trial high arms (8–12 mg weekly); more is not shown to be better and GI/HR burden rises with dose. forum
Low-dose camp: Some claim big loss on “low” reta — selection bias and concurrent diet are huge confounders on X. anecdote
Dose camps people actually compare: Micro 0.25–0.5 for already-lean “partitioning” talk vs 2 mg trial-style start vs hold 4–9 vs chase 12. Lowest-effective is the loud rule; 12 is the headline number people quote. forum
Community trial-mimic ladder: Many research-chem logs copy ~2 mg × 4 weeks → 4 mg × 4 weeks → 8 mg × 4 weeks → optional 12 mg, holding any step if sides dominate. forum
Sweet-spot talk: 4–8 mg often framed as efficacy/tolerability compromise in Phase 2; Phase 3 adds 9 mg as a major intermediate. Individuals vary widely. forum
Missed dose (community heuristics): Take when remembered if not close to next weekly day; if near next dose, skip — practices vary; no approved patient label yet. forum
Vial / label uncertainty: Research-chemical mg labels, fill accuracy, and identity are unreliable vs GMP trial drug — dose math on unlabeled powder is a major risk. forum
Gray vial math: Research-chem mg labels are the whole risk — the same “2 mg” on two vendors is not a trial kit. forum
Frequency: Once weekly SC is the clinical and default community standard; ~6-day half-life underpins weekly, not daily, dosing. trial
Framing: Trial arms and community research-chemical practices only — not medical advice, not approved labeling, not a recommendation to use. forum
Phase 2 obesity weekly maintenance bands: 1 mg, 4 mg, 8 mg, 12 mg SC once weekly after escalation (NCT04881760). trial
Phase 2 obesity starts: The 4/8 mg target arms used 2 mg or 4 mg starts; the 12 mg arm started at 2 mg. Protocol escalation used about four-week steps, with 2 mg starts showing less GI burden than 4 mg. The fixed 1 mg arm was separate. trial
Phase 2 obesity illustrative ladder talk: Public secondary sources map multi-step climbs toward 4 / 8 / 12 mg (e.g., early low steps then 2 → 4 → 8 → 12 mg style); exact internal kit schedules are protocol-defined — use primary protocol language when available. trial
Phase 2 T2D bands: Maintenance 0.5 mg, 4 mg (2 mg start or no escalation), 8 mg (2 mg or 4 mg start), 12 mg (2 mg start), plus dulaglutide 1.5 mg and placebo comparators. trial
Phase 3 TRIUMPH dose set: Public designs emphasize 4 mg, 9 mg, and 12 mg weekly (Phase 2’s 8 mg often replaced by 6/9 mg-style intermediate steps in Phase 3 ladders). trial
Phase 3 titration (TRANSCEND / TRIUMPH comms): Common public description: start 2 mg weekly, increase every 4 weeks — e.g., 2 → 4 for 4 mg target; 2 → 4 → 6 → 9 for 9 mg; 2 → 4 → 6 → 9 → 12 for 12 mg (longer climb than Phase 2). trial

How it may feel 10

Days 1–7: First appetite drop, early fullness, mild nausea — or almost nothing until dose rises; injection-day fatigue sometimes noted. forum
Weeks 1–4 (start band): GI events cluster at initiation; trial data favored 2 mg starts over 4 mg starts for tolerability. Community microstarters (0.25–0.5 mg) report quieter onboarding. Inspected accounts also describe no response at 1–4 mg or marked effects after a source switch; lower gray-vial amounts are not established as gentler. trialforum
Weeks 8–16: Steep early scale change if calories crash; individual “food noise gone” vs “I can’t eat enough protein” split shows. forum
First weeks vs later: Starter reports range from almost nothing to “I forgot lunch”; escalation can re-flare nausea and make protein intake difficult. The 4–5 week steady-state explanation is community PK lore, not a measured timetable for subjective quiet or a day-one guarantee. forum
Women’s threads: Protein-can’t-finish, stall-at-4 mg, and “is tirz better for food noise?” dominate women’s reta groups — not a separate molecule. forum
Weeks 4–12 (escalation ladder): Each 4-week step can re-flare nausea/vomiting/diarrhea/constipation; hold-or-step-down is common when food intake collapses or vomiting repeats. trial
Months 3–6: Phase 2 24-week means already large at higher doses; many community logs debate hold at 4–8 mg vs push toward 9–12 mg. trial
Months 6–12: Phase 2 48-week data still well above placebo; real-world users report rate-of-loss slowing as body weight falls — expected with any large deficit. trial
Months 12–20+ (Phase 3 windows): TRIUMPH-scale multi-month means at 9–12 mg still climbing in toplines for some cohorts; long-run maintenance is the clinical model. trial
Heart-rate arc: Dose-dependent resting HR rise tends to peak around ~24 weeks then partially decline while remaining above baseline in Phase 2 descriptions. trial

Around the dose 7

Clock: Weekly. Same “pick a day and keep it” habit as other incretins. forum
Food: Protein floor + lifting is the recomp pairing people repeat, because appetite drop can be steep. forum
Training: Don’t drop weights because eating got easy to skip. forum
After: Fatigue/nausea windows — people plan harder sessions off the worst day, not on it. forum
Alcohol: Some report drink-thinking dropped; shot-day booze is a nausea story. forum
Mechanical eating: When food noise dies, people set protein alarms or shakes so training doesn’t starve. forum
Women vs men (loud split): Women’s logs argue protein floor and stall-dose more; men’s lean-microdose “recomp” talk is louder on X. Same weekly pin. forum

Cycles people discuss 8

Community “cycle” structure: Long escalation ladder → hold a tolerable maintenance dose at goal pace → optional slow down-titration. forum
Hold vs escalate: Forum advice favors remaining at an amount that controls appetite/weight change rather than chasing the headline maximum; harsh GI effects are a recurring concern. This is attributed community advice, not a validated self-directed rule. forum
Time off / washout: Inconsistently described; rebound hunger and regain drive continuous-use vs intermittent debates. Pharmacologically, multi-week residual exposure after last shot is expected. forum
Restart rule of thumb (forums): Restarting at a lower step is often discussed because a prior high amount may renew GI effects. There is no approved patient label or universal safe restart rule established by these posts. forum
Not stacked as a short “cut cycle” with AAS by design: Some PED forums still pair it that way — confounded, not clinical practice. anecdote
Clinical model: Chronic once-weekly therapy for many months to years — not a 6–8 week bodybuilding “blast.” trial
Time on: Phase 2 ran 36–48 weeks; Phase 3 windows extend to ~68–80+ weeks with extensions past 100 weeks in some arms — continuous exposure is the studied pattern. trial
After goal weight: Maintenance dose (sometimes lower than peak loss dose) vs full stop — stop associates with regain risk across the incretin class. trial

Timing 10

Weekly feel (anecdote): Some report strongest appetite curb in the first 1–3 days post-shot with slight easing before next dose — others describe flat weekly control. anecdote
Missed week: Plasma levels fall but do not fully clear before the next scheduled dose if only one week is missed. forum
Half-life: Approximately 6 days (~144 hours) after SC dosing — supports once-weekly administration. trial
PK character: Dose-proportional pharmacokinetics described in development; fatty-diacid albumin engagement prolongs exposure. trial
Steady state: Roughly 4–5 half-lives → ~4–5 weeks of consistent weekly dosing at a given step before exposure stabilizes. trial
Tmax window (Phase 1 summary talk): Peak concentrations often discussed in a ~12–72 hour post-dose range in secondary PK write-ups. trial
Why weekly, not daily: Long half-life; trials and forums converge on weekly SC, not multi-daily pens. trial
Clearance after stop: Meaningful residual drug for ~several weeks (rule-of-thumb ~5 half-lives ≈ ~30 days for substantial decline) — sides and appetite effects can lag. trial
Heart rate time course: Dose-dependent HR increase peaking ~24 weeks then partial decline thereafter in Phase 2 obesity data. trial
Downstream timelines: Appetite can shift within days; weight, HbA1c, and liver-fat changes build over weeks–months. trial

Stacks 10

Protein + resistance training: Default non-drug pairing to limit lean-mass loss during large deficits — more consensus than any peptide add-on. forum
Electrolytes / hydration / fiber: Practical GI and constipation supports; anti-nausea strategies (ginger, prescribed antiemetics in clinical settings) discussed more than exotic stacks. forum
Avoid dual full-dose incretin stack: Generally not combined with full-dose semaglutide or tirzepatide (redundant pathway load, amplified GI, unknown safety). Switch rather than stack is the common rule of thumb. forum
Low-dose reta + low-dose tirz (clinic/forum minority talk): Some anecdotal protocols claim complementary glucagon vs dual-agonist effects — unvalidated, not trial-supported, higher complexity and risk. anecdote
GH-axis chatter: CJC-1295/Ipamorelin, tesamorelin, or MK-677 sometimes added for recovery/sleep/comp optics during aggressive cuts — outcomes confounded. forum
Healing / joint stacks: BPC-157, TB-500 / TB-4, GHK-Cu (or GLOW-style blends) appear in “stay training while cutting” logs — no controlled evidence with retatrutide. forum
Metabolic adjacency: AOD-9604, 5-Amino-1MQ, MOTS-c, mitochondrial compounds occasionally named — speculative stacking culture. forum
Lifestyle stack: Steps, sleep, adequate absolute protein (community targets often ≥1.6–2.2 g/kg ideal or goal weight — individual), and not under-fueling into gallstone/dehydration risk. forum
What is usually NOT stacked: Other glucagon-pathway investigationals, high-dose stimulant “fat burners,” or overlapping gray-market multi-agonist powders of unknown content. forum
Cagri add-on for food noise: A minority add low-dose cagrilintide when reta quiets the scale but not the chatter — side burden jumps; not a trial combo. anecdote

Access talk 7

RUO label vs influencer dose talk: Vendors print “research use only / not for human consumption” while affiliate posts explain weekly pins. That split is the 2026 enforcement hook. forum
Code-word commerce: “Ratatouille,” “peps,” Discord/Telegram/WhatsApp middlemen, and China-bulk + third-party test culture are how people describe getting it. forum
Clinic / med-spa ads: 2026 investigations described licensed clinics advertising retatrutide anyway — still unapproved, still not a trial kit. forum
Manufacturer lawsuits: 2026 suits against U.S. sellers (pharmacies, spas, online shops) are the patent-and-unapproved-drug war, not proof a given vial is real. forum
Prescription vs gray: There is no legitimate retail prescription path outside a trial. Everything else is gray. forum
No approved product: Retatrutide is still investigational. There is no branded pen to copy, so the sema/tirz “shortage compounding” story does not apply. trial
Cannot lawfully be compounded as a copy: 2026 FDA language treats retatrutide as not a component of an approved drug and not a shortage-list substance — “compounded reta” through a U.S. telehealth shop is the same legal bucket as gray RUO in those writeups. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 9

Watch for 22

Gallbladder / biliary: Rapid weight loss + incretin class association with gallstones / biliary events — RUQ pain, fever, jaundice are medical red flags. forum
Dehydration / kidney stress: Vomiting, low intake, and diuretic habits can compound — electrolytes and fluid intake are standard community cautions. forum
Injection site: Local redness, itch, or irritation with technique/rotation lapses. forum
Fatigue, headache, hair shedding talk: Reported in forums during aggressive loss (often multifactorial: deficit, protein, micronutrients) — not uniquely proven drug-specific. anecdote
Insomnia / stimulation feel (minority): Occasional community reports of sleep disruption or “wired” feel attributed to glucagon tone — inconsistent. anecdote
Gray-market quality risks: Mislabeling, under/over-fill, contamination, wrong sequence, and non-sterile production can dominate real-world harm vs textbook pharmacology. forum
GI still rules: Nausea/fatigue still dominate early reports; “stronger” often means harsher titration for some. forum
Vendor / clinic collapse talk: Warning letters, spa advertising, and 2026 manufacturer lawsuits against U.S. sellers are the access-risk story, not a quality stamp. forum
Counterfeit / wrong peptide: Third-party testing culture exists because some vials may not be retatrutide at all. forum
Exposure-report chatter: 2026 reporting described a jump in poison-center exposures as DIY use spread — harm-signal talk, not a dose chart. forum
GI (trial + community — most common): Nausea, vomiting, diarrhea, constipation, abdominal discomfort — dose-related, mostly mild–moderate, peak around escalation; lower starting dose (2 mg vs 4 mg) partially mitigated events in Phase 2. trial
GI rates (Phase 2 order of magnitude): Nausea reported across a wide band by dose (public summaries often cite roughly mid-teens % at low dose up to ~45–60% at high dose depending on arm/table); vomiting, diarrhea, constipation also elevated vs placebo. Exact % belong to the published tables. trial
Discontinuations: Phase 2 adverse-event discontinuation was 6–16% across retatrutide groups versus none on placebo; GI events were the most common cause, not necessarily that entire percentage. Lilly’s TRIUMPH-1 release reported AE discontinuation 4.1/6.9/11.3% at 4/9/12 mg versus 4.9% placebo. Its congress summary reported GI-related discontinuation 2.2–4.6% versus 1.2%. These are separate populations/endpoints. trial
Heart rate: Dose-dependent resting HR increase; Phase 2 obesity placebo-adjusted increase on the order of ~5–6+ bpm discussed at later visits, peaking ~24 weeks then partially declining. Glucagon activity is often cited as a contributor vs pure GLP-1s. trial
Dysesthesia (Phase 3 signal): Abnormal skin sensations (odd/painful touch) reported more than placebo — e.g., TRIUMPH-4 public figures ~8.8% at 9 mg and ~20.9% at 12 mg vs ~0.7% placebo; often mild–moderate and frequently resolving; not a highlighted Phase 2 signal in the same way. trial
Lean mass / under-fueling: Large total weight loss includes some fat-free mass; low protein + no lifting during crash deficits worsens strength and composition outcomes. trial
Pancreatitis flag: Severe persistent abdominal pain radiating to the back is treated as urgent across the class; rare events appear in trial safety narratives. trial
Hypoglycemia context: Greater concern when combined with insulin or insulin secretagogues in diabetes care settings; less prominent as monotherapy in non-diabetic obesity trials but still discussed. trial
Thyroid C-cell class caution: Rodent C-cell tumor signal is a GLP-1-class labeling theme (MTC / MEN2 discussions on approved agents); human relevance remains a labeled caution framework, and retatrutide is not yet an approved label. animal
Not approved / not trial-equivalent: Research vials ≠ Phase 2/3 drug product ≠ future pharmacy brand; using them is outside regulated care. trial
Who trials excluded: Arrhythmia histories and other higher-risk groups were often excluded — safety there is poorly characterized. trial
Not compoundable as a copy: No approved product, never on the shortage list — “compounded reta” and RUO vials are the same 2026 enforcement target. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 18

Doses people talk about 20

How it may feel 10

Around the dose 7

Cycles people discuss 8

Timing 10

More on what it is 11

Stacks 10

Access talk 7

Storage notes 2

Related 9

Watch for 22

Timing context & sources